Recent news on G-Csf

Research and Markets: Gain an Insight into Mayne Pharma, One of ...  -  25 May 2007
Genetic Engineering News (press release),This currently covers only one product, however: G-CSF, which should enter trials shortly. The original deal also included EPO, but this was dropped in

Cleveland BioLabs Protectan CBLB612 Produces Breakthrough in Bone ...  -  May 21, 2007
PR Newswire (press release),This compares to the current clinical practice of administering a single purified cytokine, such as G-CSF (Neupogen(R), Granocyte(R), Neulasta(R)).

Pharma firms see gains in niche areas  -  May 13, 2007
Times of India,In February this year, Ranbaxy signed a development and marketing agreement with Zenotech Laboratories for its first biosimilar product, G-CSF (filgrastim).

Cleveland BioLabs Protectan CBLB612 Produces Breakthrough in Bone ...  -  May 21, 2007
PR Newswire (press release),In addition, Protectan CBLB612 could be used in treating those individuals that do not respond to G-CSF. In addition to efficacy in stimulation and

Former Immunex Management Team Chosen to Head-Up CTI Subsidiary ...  -  May 14, 2007
PR Newswire (press release),The therapy has the potential to be dosed once per chemotherapy cycle similar to some currently marketed G-CSF products, such as Neulasta(R).

Ranbaxy Laboratories Q1 2007 Net Profit rises 79% to Rs 129 Crores  -  Apr 27, 2007
Equity Bulls,Ranbaxy will commit its resources to introduce the G-CSF product first in the EU markets and later in the US and other countries. The worldwide market for

Maxygen Files Universal Shelf Registration Statement  -  May 16, 2007
PR Newswire (press release),...trials include a novel interferon-alpha for the treatment of hepatitis C virus (HCV) infection and a novel G-CSF for the treatment of neutropenia.

Family in need of assistance  -  Apr 25, 2007
100 Mile House Free Press,...called G-CSF prior to each round of chemotherapy. G-CSF brings white blood cell counts up quickly, eliminating excessive wait-times between treatments.

Maxygen Reports First Quarter 2007 Financial Results  -  May 8, 2007
PR Newswire (press release),Quarter Highlights Include Positive Phase I Results for G-CSF Program - Encouraging Preliminary Phase I Data from Interferon-alpha HCV Program REDWOOD CITY,

My daughter could die every three weeks  -  May 16, 2007
Checkbiotech.org (press release),Sophie's doctors do have one more card up their sleeves: she could be considered for G-CSF, a treatment to stimulate the production of white blood cells.

Wockhardt reinforces European presence with Negma acquisition  -  May 9, 2007
OutSourcing-Pharma.com,...erythropoietin, hepatitis B vaccine, interferon alpha 2B, Glargine (long-acting insulin) and granulocyte-colony stimulating factor (G-CSF).

Biotech industry to touch $5 bn in three years  -  May 6, 2007
Times of India,...including Epogen, Novolin and Humulin. The focus would be primarily in product categories such as EPO products, Human Insulin, Interferons, G-CSF.

Biotech market to reach $5 bln  -  May 7, 2007
Central Chronicle,The focus on this sector would be primarily in product categories such as-EPO products, Human Insulin, Interferons, G-CSF.

Beyond Biogenerics - The Real Threats For Therapeutic Proteins  -  Apr 27, 2007
Medical News Today (press release),Apart from biogenerics, the US$ 42 bln market of the major therapeutic proteins (EPO, insulin, coagulation factors, interferons, G-CSF, hGH,

2007 BIO International Convention Exhibitor Profiles, A Through D  -  May 3, 2007
Genetic Engineering News (press release),To improve protein drug efficacy, Amoytop has developed the following pegylated drugs (all in preclinical): Peg-G-CSF, Peg-IFN alpha-2a, Peg-IFN alpha-2b,

Family in need of assistance  -  26 Apr 2007
100 Mile House Free Press,...called G-CSF prior to each round of chemotherapy. G-CSF brings white blood cell counts up quickly, eliminating excessive wait-times between treatments.

Beyond Biogenerics: The Real Threats for Therapeutic Proteins  -  26 Apr 2007
PharmaLive.com (press release),Apart from biogenerics, the US$ 42 bln market of the major therapeutic proteins (EPO, insulin, coagulation factors, interferons, G-CSF, hGH,

Maxygen to Present Review of G-CSF Clinical Program Live at NASDAQ ...  -  Apr 10, 2007
PharmaLive.com (press release),Products developed by Maxygen now in clinical trials include a novel G-CSF for the treatment of neutropenia and a novel interferon-alpha for the treatment

Maxygen to Present Review of G-CSF Clinical Program Live at NASDAQ ...  -  Apr 10, 2007
Earthtimes.orgApril 17, 2007, to review its development program for MAXY-G34, Maxygen's next- generation G-CSF drug for the treatment of neutropenia.

Maxygen First Quarter 2007 Financial Results Conference Call Notice  -  Apr 25, 2007
PharmaLive.com (press release),...trials include a novel interferon-alpha for the treatment of hepatitis C virus (HCV) infection and a novel G-CSF for the treatment of neutropenia.

Cleveland BioLabs Protectan CBLB612 Demonstrates Efficacy in ...  -  Apr 20, 2007
PR Newswire (press release),Effect of Single Dose of Protectan CBLB612 on Proportion of Free Floating Hematopoietic (Bone Marrow) Stem Cells Comparable to Four Doses of G-CSF CLEVELAND

Cleveland BioLabs Protectan CBLB612 Demonstrates Efficacy In ...  -  Apr 21, 2007
Medical News Today (press release),G-CSF is a human growth factor that works by inducing bone marrow to produce more white blood cells and early hematopoietic stem cells in particular.

CoGenesys, Inc. Expands Clinical Programs with Initiation of Phase ...  -  Mar 27, 2007
PipelineReview.com (press release),In designing the trial, we have benefited from the fact that G-CSF is a well-characterized compound which has been studied in a number of patient

CoGenesys begins research on infection drug  -  Mar 28, 2007
Pharmaceutical Business ReviewNeugranin is a long-acting form of Granulocyte Colony Stimulating Factor (G-CSF). CoGenesys believes that Neugranin has the potential to be the second

Donald Metcalf Receives American Association for Cancer Research  -  Apr 4, 2007
WebWire (press release),Exploiting this, his collaborators documented the effectiveness of GM-CSF and G-CSF (two primary white blood cell regulators) when injected into patients.

Stem Cells Tame Type 1 Diabetes in Pilot Study  -  Apr 10, 2007
MedPage Today,The patients were first treated with cyclophosphamide (Cytoxan) 2.0 g/m 2 ) and G-CSF (10 μg/kg per day) to mobilized the stem cells, which were then

3SBio Inc. Announces Fourth Quarter And Fiscal Year 2006 Results  -  Apr 5, 2007
Drug Newswire (press release),Tietai Iron Sucrose Supplement and Baolijin, our recombinant human granulocyte colony-stimulating factor or G-CSF, in-licensed in May and August 2006,

BioGeneriX and Neose Announce Initiation of 2nd Phase I Clinical ...  -  Mar 21, 2007
PharmaLive.com (press release),Our aim is to develop GlycoPEG-GCSF to compete effectively in the long-acting G-CSF market," said George J. Vergis, Ph.D., Neose president and chief

Breast cancer chemo can carry leukemia risk  -  Mar 16, 2007
The Australian,But for the women who received growth factors (mainly G-CSF), the risk of getting leukemia was twice as great as for the others.

Maxygen to Present at the Cowen and Company 17th Annual Health ...  -  Mar 6, 2007
Genetic Engineering News (press release),Russell Howard , Maxygen's chief executive officer, will present results from the Phase I clinical trial of MAXY-G34, the company's next- generation G-CSF

Drugs to boost immune system during chemo may hike risks  -  Mar 5, 2007
Jackson Clarion Ledger,Growth factors such as G-CSF, known by the trade name Neupogen, and GM-CSF boost the patient's production of white blood cells.

In search of a matching donor  -  Mar 21, 2007
Excalibur Online,To increase cell development, doctors inject donors with granulocyte colony stimulating factor (G-CSF) everyday for four to five days.

Biotech Knockoffs  -  Mar 15, 2007
Forbes,...versions of some simpler proteins, such as human growth hormone and G-CSF, which stimulates white blood cell production following chemotherapy.

Roche Ending Maxygen Deal For Factor VII Over De-Risk'  -  Mar 14, 2007
BioWorld Online,Separately Wednesday, Maxygen disclosed Phase I results with MAXY-G34, a next-generation granulocyte-colony stimulating factor (G-CSF) product for

Pharma firms team up to spread reach  -  Mar 5, 2007
Business Standard,Recently, Ranbaxy Laboratories tied up with the Hyderabad-based Zenotech Laboratories for the global development and marketing of G-CSF (filgrastim) to mark

US set to pass generic biotechs Bill this year  -  Mar 4, 2007
Daily News & Analysis,Zenotech, along with Ranbaxy is working on G-CSF, which is a generic copy of Filgrastim, which is used for preventing infections during cancer treatment.

Natural supplement can boost your stem-cell count  -  Feb 28, 2007
Canadian Jewish News,...“There is a compound injected in the blood called G-CSF, granulocyte colony-stimulating factor, which stimulates the release of stem cells from the bone

Changes in US law a good thing for local pharma  -  Feb 25, 2007
Daily News & Analysis,Zenotech has tied up with Ranbaxy to develop and market its first bio-similar product, G-CSF - filgrastim, for preventing infections in cancer treatment.

Stroma-derived factor (SDF-1/CXCL12) and human tumor pathogenesis  -  Mar 8, 2007
AJP - Cell Physiology (subscription)Zipori D, Lapidot T. G-CSF induces stem cell mobilization by decreasing bone marrow SDF-1 and up-regulating CXCR4. Nat Immunol 3: 687–694, 2002.

Changes in US law a good thing for local pharma  -  25 Feb 2007
Daily News & Analysis,Zenotech has tied up with Ranbaxy to develop and market its first bio-similar product, G-CSF - filgrastim, for preventing infections in cancer treatment.

Ranbaxy inks pact with Zenotech for G-CSF product  -  Feb 6, 2007
Myiris.com,Ranbaxy Laboratories (Q, N,C,F)* has signed a global development and marketing agreement with Zenotech Laboratories for its first biosimilar product, G-CSF

Growth Factors Given With Chemotherapy Associated With Increased ...  -  Feb 9, 2007
Medical News Today (press release),The growth factors granulocyte or granulocyte-macrophage colony-stimulating factor (G-CSF or GM-CSF) have been used to reduce the risk of infections from

Immunity Boosters May Raise Leukemia Risk  -  Feb 6, 2007
CBS News,But 1.77 percent of the women treated with G-CSF or GM-CSF developed leukemia. Statistically, the drugs seemed to double a woman's leukemia risk—although

Ranbaxy Announces Global Entry into Biosimilars with Zenotech ...  -  Feb 7, 2007
India PRwire (Press Release),Ranbaxy has taken a strategic decision to commit resources to introduce the G-CSF product for global marketing beginning with markets in the EU where

Growth Factors for Breast Cancer Linked to Leukemia  -  Feb 7, 2007
MedPage Today,The relative risk of the two conditions for women 65 or older treated with either granulocyte colony stimulating factor (G-CSF) or granulocyte-macrophage

Ranbaxy announces global entry into biosimilars with Zenotech  -  Feb 8, 2007
Prdomain Business Register (press release),G-CSF is used to prevent infections from cancer chemotherapy-induced neutropenia (decrease in the number of a type of white-blood cells).

Ranbaxy enters biosimilar product space with Zenotech, targets EU ...  -  Feb 8, 2007
domain-B,Mumbai: Ranbaxy Laboratories has signed a global development and marketing agreement with Zenotech Laboratories Ltd for its first biosimilar product, G-CSF

Indian-Irish biosimilar partnership to provide new European CMO ...  -  Feb 13, 2007
OutSourcing-Pharma.com,...although it does not have regulatory-approved microbial cell culture capabilities for the drugs that require this, such as G-CSF.

Indian firm, Ranbaxy, eyes up biosimilars  -  Feb 9, 2007
BiopharmaReporter.com,If successful, Ranbaxy's G-CSF, a drug that encourages white blood cell production, might be the first Indian biosimilar to be launched in Europe.

Ranbaxy forays biosimilars via Zenotech tie-up  -  Feb 7, 2007
Business Standard,According to an official release issued by the company to the BSE today, G-CSF is used to prevent infections from cancer chemotherapy-induced neutropenia

Brain study offers clues into why humans do good  -  Jan 30, 2007
Asbury Park Press,Granulocyte colony-stimulating factor (G-CSF) — a medication commonly used to help reduce the toxic effects of chemotherapy in cancer patients - also caused

Ranbaxy forays into biosimilar products  -  Feb 7, 2007
Hindu,7 (PTI): Ranbaxy today said it has forged a marketing and global development agreement with biopharma firm Zenotech for its first biosimilar product G-CSF

India's Ranbaxy forays into biosimilar products  -  Feb 7, 2007
IRNA,India's Ranbaxy Tuesday said it has forged a marketing and global development agreement with biopharma firm Zenotech for its first biosimilar product G-CSF

Ranbaxy forays into biosimilar products space with Zenotech  -  Feb 7, 2007
Zee News,G-CSF is used for preventing infections from cancer chemotherapy-induced neutropenia (decrease in the number of a type of white-blood cells) -- the

Cell Therapeutics Spin-off to Use Genetic Technology to Develop ...  -  Feb 13, 2007
GenomicsProteomics.com (press release),The first biologics the Company plans to move into preclinical study include a long-acting G-CSF and EPO biosimilar.

Ranbaxy to sell Zenotech infection drug in Europe  -  Feb 7, 2007
Reuters India,The global market for G-CSF, used to prevent infections caused by the reduction of white blood cells during chemotherapy, is about $1.6 billion,

Zenotech ties up with Ranbaxy for EU market  -  Feb 7, 2007
Moneycontrol.com,The global market for neutropenia treatments is in excess of $4 billion, while the global G-CSF market is about $1.6 billion. ZLL, a four-year-old,

Reliance, Ranbaxy enter bio-similar drugs market  -  Feb 7, 2007
Financial Express,...“The global sales for EPO alone is $10 billion while that of G-CSF is $3 billion," Subramaniam said. Although there were global players like Amgen,

Infection-Fighting Cancer Treatment Could Boost Leukemia Risk  -  Feb 7, 2007
Atlanta Journal Constitution (subscription),Of the total, 906 women received either granulocyte colony-stimulating factor (G-CSF) or granulocyte-macrophage colony-stimulating factor (GM-CSF), or both.

Risk still low on drugs to aid immunity  -  Feb 7, 2007
Chicago Tribune,Growth factors such as G-CSF (granulocyte colony-stimulating factor), known by the trade name Neupogen, and GM-CSF (granulocyte-macrophage

Cancer support care may up blood diseases  -  Feb 6, 2007
United Press InternationalSixteen percent of the patients were treated with growth factors G-CSF, GM-CSF, or both. The researchers said the increase in the blood disorders might be

Cell Therapeutics, Inc. Spin-off to Use Proprietary Recombinant ...  -  Feb 12, 2007
PharmaLive.com (press release),The first biologics the Company plans to move into preclinical study include a novel, long-acting G-CSF and EPO biosimilar.

Cell Therapeutics, Inc. (CTI) Spin-off to Use Proprietary ...  -  Feb 12, 2007
PR Newswire (press release),The first biologics the Company plans to move into preclinical study include a novel, long-acting G-CSF and EPO biosimilar. Bianco will discuss in further

US law promises new biz avenue for India  -  Feb 18, 2007
Central Chronicle,Zenotech Laboratories to produce its first biosimilar, a Granulocyte-colony stimulating factor (G-CSF; filgrastim) for chronic renal failure.

Growth Factors May Increase Risk of AML and MDS in Post-menopausal ...  -  Feb 15, 2007
Cancer Consultants (press release),The evidence for a potential role of G-CSF in the onset of AML/MDS, derived from only a few retrospective studies, thus has to be qualified as hypothesis

Business Briefs:  -  Feb 7, 2007
Daily Times,MUMBAI: India’s top drug maker by sales, Ranbaxy Laboratories Ltd has signed a deal to market Zenotech Laboratories Ltd’s generic biotech drug G-CSF in

Ranbaxy ties up with Zenotech  -  Feb 7, 2007
Financial Express,...“G-CSF will lead the way for the development of other bio-similar molecules within our portfolio,� chief executive officer of Zenotech Labs Jayaram

Maxygen Reports Fourth Quarter and Year End 2006 Financial Results  -  Feb 6, 2007
Earthtimes.org2006 Highlights -- Maxygen initiated Phase I clinical trials for MAXY-G34, Maxygen's next-generation G-CSF to treat neutropenia. -- Roche initiated Phase Ia

Researchers Urge Monitoring Of Bone Health During Chemotherapy  -  Jan 15, 2007
Medical News Today (press release),Weilbaecher and her colleagues found that when they gave mice an eight-day course of the growth factor, called granulocyte colony-stimulating factor (G-CSF)

Continence program for women  -  Jan 16, 2007
Belleville News-Democrat,The medication in question is growth factor G-CSF, which is commonly used to help cancer patients recover healthy blood counts after chemotherapy,

Cancer therapy may weaken bones  -  Jan 12, 2007
United Press International..."We are not at all advocating ending G-CSF use," says Weilbaecher, an oncologist with the Siteman Cancer Center at Washington University School of Medicine

Cleveland BioLabs Protectans Technology Yields Stem Cell Research ...  -  Jan 11, 2007
Medical News Today (press release),G-CSF is a human growth factor that works by inducing bone marrow to produce more white blood cells. In the Company's experiments with Protectan CBLB612,

CoGenesys Files To Begin Clinical Trials Of Neugranin For The ...  -  Jan 5, 2007
Medical News Today (press release),Neulasta(R) is the only long-acting G-CSF product presently approved in the world. Neulasta alone generated $2.2 billion in sales in 2005.

Mitoxantrone-based Therapy Increases Risk for Subsequent Leukemia ...  -  Jan 12, 2007
Cancer Consultants (press release),Patients treated with granulocyte colony-stimulating factor (G-CSF) also appeared to have an increased risk of developing AML or MDS.

Dose-Dense Chemotherapy for Osteosarcoma Yields No Survival Benefit  -  Jan 16, 2007
MedPage Today,The latter were condensed into six two-week cycles plus 5 μg/kg granulocyte colony stimulating factor (G-CSF) on days four to 13 of each cycle to increase

Neose and BioGeneriX Extend GlycoPEG-GCSF Collaboration ...  -  Dec 29, 2006
PharmaLive.com (press release),G-CSF is prescribed to stimulate the production of neutrophils, and is approved for sale in major markets around the world for the treatment of neutropenia

Dutton Associates Announces Investment Opinion: Chemokine ...  -  Jan 12, 2007
Genetic Engineering News (press release),...and third stage of this study (the third stage combines CTCE-0214 with granulocyte colony stimulating factor (G-CSF)) to be reported in this time frame,

Dutton Associates Announces Investment Opinion: Chemokine ...  -  Jan 12, 2007
Business Wire (press release),...and third stage of this study (the third stage combines CTCE-0214 with granulocyte colony stimulating factor [G-CSF]) to be reported in this time frame,

Follow-Up Data on Dose-Dense Chemotherapy Confirms Benefit in ...  -  Jan 10, 2007
Cancer Consultants (press release),...paclitaxel 225 mg/m2 and cyclophosphamide 2500 mg/m2) administered once every 2 weeks with granulocyte colony stimulating factor (G-CSF) support,

AVEO Acquires Clinical Stage Anti-Cancer Compound From Kirin  -  Jan 6, 2007
Medical News Today (press release),It markets erythropoietin for end-stage renal disease and G-CSF for cancer patients in Asia. The company is committed to scientific progress,

Dr. David U'Prichard Joins CoGenesys Board of Directors  -  Dec 19, 2006
PR Newswire (press release),CoGenesys is also developing Neugranin(TM), a long-acting form of Granulocyte Colony Stimulating Factor (G-CSF), to decrease the incidence of infection in

Amrubicin Shows Promise As Small-Cell Lung Cancer Treatment  -  Jan 4, 2007
Cancerpage.com,Myelosuppression affecting primarily leukocytes was the most frequent toxicity, requiring G-CSF administration to 42 patients (70%), the investigators note.

Biotech Stocks Day-in-Review: Amgen Strikes Drug Deal With ...  -  Jan 4, 2007
Seeking Alpha,...has asked European authorities to allow the start of human studies of Neugranin, a long-acting form of Granulocyte Colony Stimulating Factor [G-CSF].

MGI Pharma Announces Publication of Phase 2 Data Describing ...  -  Jan 3, 2007
PharmaLive.com (press release),The use of erythropoietin and granulocyte colony-stimulating factor (G-CSF) were allowed as indicated by the clinical condition. Patients received at least

Re-Induction Chemotherapy May Improve Survival for Some Patients ...  -  Jan 2, 2007
Cancer Consultants (press release),...were all initially treated with 6 courses of PEV (Platinol® (cisplatin), Ellence® (epirubicin), Navelbine® (vinorelbine) every 14-21 days plus G-CSF.

New Insight Into How The Brain Regenerates After Stroke  -  Dec 23, 2006
Science Daily (press release)In a JCI study scientists describe new roles for G-CSF in treating stroke and other central nervous system roles of this ... > full story

Chemokine Therapeutics Announces Results From CTCE-0214 Clinical ...  -  Dec 23, 2006
Medical News Today (press release),..."The third part of the phase Ib trial should provide us with additional information on the benefits of combining CTCE-0214 with G-CSF."

Chemokine Therapeutics Announces Results From CTCE-0214 Clinical ...  -  Dec 22, 2006
PipelineReview.com (press release),...“The third part of the phase Ib trial should provide us with additional information on the benefits of combining CTCE-0214 with G-CSF.�

Chemokine Therapeutics announces results from CTCE-0214 clinical ...  -  Dec 21, 2006
CNW Telbec (Communiqués de presse),..."The third part of the phase Ib trial should provide us with additional information on the benefits of combining CTCE-0214 with G-CSF.

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional